Overcoming Resistance to Targeted Anticancer Therapies through Small-Molecule-Mediated MEK Degradation

Jessie Peh, Matthew W. Boudreau, Hannah M. Smith, Paul Hergenrother

Research output: Contribution to journalArticle

Abstract

The discovery of mutant or fusion kinases that drive oncogenesis, and the subsequent approval of specific inhibitors for these enzymes, has been instrumental in the management of some cancers. However, acquired resistance remains a significant problem in the clinic, limiting the long-term effectiveness of most of these drugs. Here we demonstrate a general strategy to overcome this resistance through drug-induced MEK cleavage (via direct procaspase-3 activation) combined with targeted kinase inhibition. This combination effect is shown to be general across diverse tumor histologies (melanoma, lung cancer, and leukemia) and driver mutations (mutant BRAF or EGFR, fusion kinases EML4-ALK and BCR-ABL). Caspase-3-mediated degradation of MEK kinases results in sustained pathway inhibition and substantially delayed or eliminated resistance in cancer cells in a manner far superior to combinations with MEK inhibitors. These data suggest the generality of drug-mediated MEK kinase cleavage as a therapeutic strategy to prevent resistance to targeted anticancer therapies. Rapid onset of resistance to targeted kinase inhibitors limits their use in treating advanced cancers. Peh et al. show that combination of diverse kinase inhibitors with a procaspase-3 activating compound (PAC-1) leads to degradation of MEK1/2, dramatically delaying acquired resistance.

Original languageEnglish (US)
Pages (from-to)996-1005.e4
JournalCell chemical biology
Volume25
Issue number8
DOIs
StatePublished - Aug 16 2018

Fingerprint

Mitogen-Activated Protein Kinase Kinases
Phosphotransferases
Degradation
Molecules
Caspase 3
MAP Kinase Kinase Kinases
Neoplasms
Fusion reactions
Pharmaceutical Preparations
Therapeutics
Histology
Enzyme Inhibitors
Drug Resistance
Tumors
Melanoma
Lung Neoplasms
Carcinogenesis
Leukemia
Chemical activation
Cells

Keywords

  • apoptosis
  • cancer
  • caspase activation
  • kinases
  • resistance
  • targeted therapy

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Overcoming Resistance to Targeted Anticancer Therapies through Small-Molecule-Mediated MEK Degradation. / Peh, Jessie; Boudreau, Matthew W.; Smith, Hannah M.; Hergenrother, Paul.

In: Cell chemical biology, Vol. 25, No. 8, 16.08.2018, p. 996-1005.e4.

Research output: Contribution to journalArticle

Peh, Jessie ; Boudreau, Matthew W. ; Smith, Hannah M. ; Hergenrother, Paul. / Overcoming Resistance to Targeted Anticancer Therapies through Small-Molecule-Mediated MEK Degradation. In: Cell chemical biology. 2018 ; Vol. 25, No. 8. pp. 996-1005.e4.
@article{a9e446679ed34d5e85473e5161f6d897,
title = "Overcoming Resistance to Targeted Anticancer Therapies through Small-Molecule-Mediated MEK Degradation",
abstract = "The discovery of mutant or fusion kinases that drive oncogenesis, and the subsequent approval of specific inhibitors for these enzymes, has been instrumental in the management of some cancers. However, acquired resistance remains a significant problem in the clinic, limiting the long-term effectiveness of most of these drugs. Here we demonstrate a general strategy to overcome this resistance through drug-induced MEK cleavage (via direct procaspase-3 activation) combined with targeted kinase inhibition. This combination effect is shown to be general across diverse tumor histologies (melanoma, lung cancer, and leukemia) and driver mutations (mutant BRAF or EGFR, fusion kinases EML4-ALK and BCR-ABL). Caspase-3-mediated degradation of MEK kinases results in sustained pathway inhibition and substantially delayed or eliminated resistance in cancer cells in a manner far superior to combinations with MEK inhibitors. These data suggest the generality of drug-mediated MEK kinase cleavage as a therapeutic strategy to prevent resistance to targeted anticancer therapies. Rapid onset of resistance to targeted kinase inhibitors limits their use in treating advanced cancers. Peh et al. show that combination of diverse kinase inhibitors with a procaspase-3 activating compound (PAC-1) leads to degradation of MEK1/2, dramatically delaying acquired resistance.",
keywords = "apoptosis, cancer, caspase activation, kinases, resistance, targeted therapy",
author = "Jessie Peh and Boudreau, {Matthew W.} and Smith, {Hannah M.} and Paul Hergenrother",
year = "2018",
month = "8",
day = "16",
doi = "10.1016/j.chembiol.2018.05.008",
language = "English (US)",
volume = "25",
pages = "996--1005.e4",
journal = "Cell Chemical Biology",
issn = "2451-9448",
publisher = "Elsevier Inc.",
number = "8",

}

TY - JOUR

T1 - Overcoming Resistance to Targeted Anticancer Therapies through Small-Molecule-Mediated MEK Degradation

AU - Peh, Jessie

AU - Boudreau, Matthew W.

AU - Smith, Hannah M.

AU - Hergenrother, Paul

PY - 2018/8/16

Y1 - 2018/8/16

N2 - The discovery of mutant or fusion kinases that drive oncogenesis, and the subsequent approval of specific inhibitors for these enzymes, has been instrumental in the management of some cancers. However, acquired resistance remains a significant problem in the clinic, limiting the long-term effectiveness of most of these drugs. Here we demonstrate a general strategy to overcome this resistance through drug-induced MEK cleavage (via direct procaspase-3 activation) combined with targeted kinase inhibition. This combination effect is shown to be general across diverse tumor histologies (melanoma, lung cancer, and leukemia) and driver mutations (mutant BRAF or EGFR, fusion kinases EML4-ALK and BCR-ABL). Caspase-3-mediated degradation of MEK kinases results in sustained pathway inhibition and substantially delayed or eliminated resistance in cancer cells in a manner far superior to combinations with MEK inhibitors. These data suggest the generality of drug-mediated MEK kinase cleavage as a therapeutic strategy to prevent resistance to targeted anticancer therapies. Rapid onset of resistance to targeted kinase inhibitors limits their use in treating advanced cancers. Peh et al. show that combination of diverse kinase inhibitors with a procaspase-3 activating compound (PAC-1) leads to degradation of MEK1/2, dramatically delaying acquired resistance.

AB - The discovery of mutant or fusion kinases that drive oncogenesis, and the subsequent approval of specific inhibitors for these enzymes, has been instrumental in the management of some cancers. However, acquired resistance remains a significant problem in the clinic, limiting the long-term effectiveness of most of these drugs. Here we demonstrate a general strategy to overcome this resistance through drug-induced MEK cleavage (via direct procaspase-3 activation) combined with targeted kinase inhibition. This combination effect is shown to be general across diverse tumor histologies (melanoma, lung cancer, and leukemia) and driver mutations (mutant BRAF or EGFR, fusion kinases EML4-ALK and BCR-ABL). Caspase-3-mediated degradation of MEK kinases results in sustained pathway inhibition and substantially delayed or eliminated resistance in cancer cells in a manner far superior to combinations with MEK inhibitors. These data suggest the generality of drug-mediated MEK kinase cleavage as a therapeutic strategy to prevent resistance to targeted anticancer therapies. Rapid onset of resistance to targeted kinase inhibitors limits their use in treating advanced cancers. Peh et al. show that combination of diverse kinase inhibitors with a procaspase-3 activating compound (PAC-1) leads to degradation of MEK1/2, dramatically delaying acquired resistance.

KW - apoptosis

KW - cancer

KW - caspase activation

KW - kinases

KW - resistance

KW - targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85047228996&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047228996&partnerID=8YFLogxK

U2 - 10.1016/j.chembiol.2018.05.008

DO - 10.1016/j.chembiol.2018.05.008

M3 - Article

C2 - 29909991

AN - SCOPUS:85047228996

VL - 25

SP - 996-1005.e4

JO - Cell Chemical Biology

JF - Cell Chemical Biology

SN - 2451-9448

IS - 8

ER -